Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug;13(5):376-83.
doi: 10.1111/j.1399-5448.2011.00841.x. Epub 2012 Feb 15.

Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study

Collaborators, Affiliations
Randomized Controlled Trial

Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study

Fida Bacha et al. Pediatr Diabetes. 2012 Aug.

Abstract

Objective: To investigate insulin sensitivity and secretion indices and determinants of glycemic control in youth with recent-onset type 2 diabetes (T2DM) at randomization in the TODAY study, the largest study of youth with T2DM to date.

Methods: We examined estimates of insulin sensitivity [1/fasting insulin (1/I(F)), fasting glucose/insulin (G(F) /I(F)), 1/fasting C-peptide (1/C(F)), G(F) /C(F)], β-cell function [insulinogenic index (ΔI30/ΔG30), and ΔC30/ΔG30], and disposition index (DI) in the TODAY cohort of 704 youth (14.0 ± 2.0 yr; diabetes duration 7.8 ± 5.8 months; 64.9% female; 41.1% Hispanic, 31.5% Black, 19.6% White, 6.1% American Indian, and 1.7% Asian) according to hemoglobin A1c (HbA1c) quartiles at study randomization. The randomization visit followed a run-in period (median 71 d) during which glycemic control (HbA1c ≤ 8% for at least 2 months) was achieved with metformin alone. These measures were also examined in relation to screening HbA1c levels before run-in.

Results: Insulin secretion indices declined with increasing HbA1c quartiles, at randomization (ΔC30/ΔG30: 0.11 ± 0.09, 0.10 ± 0.19, 0.07 ± 0.06, and 0.03 ± 0.03 ng/mL per mg/dL, p < 0.0001; DI: 0.03 ± 0.03, 0.03 ± 0.05, 0.02 ± 0.02, and 0.01 ± 0.01 mg/dL(-1) , p < 0.0001) and at screening, with no significant difference in insulin sensitivity. There were no significant differences in estimates of insulin sensitivity or secretion between genders or across the different racial groups. At randomization and screening, HbA1c correlated with DI (r = -0.3, p < 0.001), with ΔC30/ΔG30, but not with insulin sensitivity estimates.

Conclusions: In youth with recent-onset T2DM treated with metformin, glycemic control, as measured by HbA1c, appears to be associated with residual β-cell function and not insulin sensitivity.

PubMed Disclaimer

Conflict of interest statement

Disclosures: None of the authors has any conflict of interest to declare.

Figures

Figure 1
Figure 1
(A)- 1/Fasting C-peptide (CF), (B)- ΔC30/ΔG30, (C)- DI across randomization HbA1c quartiles (left panel); (D)- 1/Fasting C-peptide (CF), (E)- ΔC30/ΔG30, (F)- DI across screening HbA1c quartiles (right panel). Unadjusted p-value, + adjusted for BMI, race and sex.

References

    1. Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D TODAY Study Group. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74–87. - PMC - PubMed
    1. Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67. - PMC - PubMed
    1. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes mellitus: Insulin resistance, beta-cell failure or both? Diabetes Care. 2005;28:638–644. - PMC - PubMed
    1. Elder DA, Woo JG, D’Alessio DA. Impaired β-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes. Pediatr Diabetes. 2010;11:314–21. - PMC - PubMed
    1. Bacha F, Gungor N, Lee S, Arslanian S. In vivo insulin sensitivity and secretion in obese youth: What are the differences between NGT, IGT and type 2 diabetes? Diabetes Care. 2009;32:100–105. - PMC - PubMed

Publication types